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To elucidate the effect of cinacalcet use on all-cause and cause-specific hospitalization out-
comes using a prospective cohort of maintenance hemodialysis patients.
Methods
We used data from a prospective cohort of Japanese hemodialysis patients with secondary
hyperparathyroidism and examined baseline characteristics as well as longitudinal changes.
All patients were cinacalcet-naïve at study enrollment. Further, we used a marginal struc-
tural model to account for time-varying confounders on cinacalcet initiation and hospitaliza-
tion outcomes, and an Andersen-Gill–type recurrent event model to account for any
recurring events of hospitalization in the outcome analysis using the weighted dataset.
Results
Among the 3,276 patients, cinacalcet treatment was initiated in 1,384 patients during the
entire follow-up. Cinacalcet users were slightly younger, included more patients with chronic
glomerulonephritis and fewer patients with diabetes, were more likely to have a history of
parathyroidectomy, and were more often used receiving vitamin D receptor activator, phos-
phate binders, and iron supplements. The overall hospitalization analysis yielded a hazard
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ratio (HR) of 0.97 (95% confidence interval [CI]: 0.80, 1.18). A trend toward a mild protective
association was observed for cardiovascular-related hospitalizations (HR: 0.85; 95% CI:
0.64, 1.14). In the subgroup analysis, a protective association was seen due to cinacalcet
use for infection-related hospitalizations in the lowest intact parathyroid hormone group
(HR: 0.36; 95% CI: 0.14, 0.95).
Conclusions
Cinacalcet initiation in patients on maintenance hemodialysis had no effect on all-cause and
cause-specific hospitalizations. Although the overall association was statistically not signifi-
cant, cinacalcet may have a protective association on cardiovascular-related hospitalization in
all patients and infection-related hospitalization in patient with low intact parathyroid hormone.
Introduction
Secondary hyperparathyroidism (SHPT) is one of the most common complications that
develop with chronic kidney disease (CKD) progression [1]. The prevalence of SHPT (serum
intact parathyroid hormone [iPTH] > 180 pg/mL according to the Japanese guideline [2]) in
dialysis patients was 32%, and the number of prevalent dialysis patients was 329,609 at the end
of 2016 [3]. The risk of cardiovascular disease is markedly elevated in patients with CKD, espe-
cially those being treated with hemodialysis [4]. SHPT patients with inadequately controlled
mineral metabolism abnormalities often develop high rotational bone lesions and cardiovascu-
lar calcification. Furthermore, serum phosphate (P), calcium (Ca), and intact parathyroid
hormone (iPTH) concentrations have been shown to be associated with all-cause and cardio-
vascular mortality in dialysis patients [5,6]. In addition, dialysis patients experience high com-
plication rates of cardiovascular diseases, infectious diseases, and vascular access (VA)-related
complications. The annual risk of hospitalization lasting more than one month was 5.9-fold
higher in Japanese dialysis patients compared with the Japanese general population [7].
Cinacalcet, an oral calcimimetic agent, modulates the Ca sensing receptor allosterically and
increases the sensitivity of parathyroid cells to extracellular Ca ions, thereby decreasing the
production and secretion of PTH and decreasing Ca and P concentrations [8]. Cinacalcet is
effective for preventing the progression of vascular calcification and cardiovascular events [9–
12]. Our previous analysis on the Mineral and Bone Disorder Outcomes Study for Japanese
Chronic Kidney Disease Stage 5D Patients (MBD-5D) show that cinacalcet therapy improved
outcomes on a composite of cardiovascular-related hospitalizations and mortality in SHPT
patients with iPTH� 300 pg/mL (incidence rate ratio [IRR]: 0.71; 95% confidence interval
[CI]: 0.53, 0.94) [13]. These results indicate that cinacalcet may reduce cardiovascular- and
VA-related hospitalizations by improving bone mineral management and inhibiting vascular
calcification. However, only a few studies have specifically investigated the effectiveness of
cinacalcet prescription on cause-specific and recurrent hospitalization.
Therefore, we conducted an analysis of the MBD-5D in order to elucidate the relationship
between cinacalcet use and the incidence of hospitalizations in SHPT management.
Materials and methods
Data source and study population
MBD-5D was a 3-year, multicenter, prospective cohort study by case-cohort design. The
eligibility criteria were as follows: (i) patients undergoing hemodialysis and (ii) patients with
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iPTH� 180 pg/mL or receiving vitamin D receptor activator (VDRA) treatment. Details of
the study design have been described previously [14]. Patients were randomly sampled from
the whole cohort to yield a “subcohort”. The whole cohort was used to investigate mortality in
a case-cohort design. Laboratory data, medication data and hospitalization outcomes were
prospectively collected at 3- or 6-month intervals from patients in the subcohort. Only the
patients in the subcohort were included in this analysis. Patients with cancer or cancer-related
comorbidities at the time of enrollment were excluded at baseline; if a patient was diagnosed
with cancer during the observation period, data obtained post-diagnosis were censored. MBD-
5D was approved by the Central Ethics Committee at the Kobe University School of Medicine
and was conducted in accordance with the principles of the Declaration of Helsinki. Informed
consent was not mandatory according to the ethical guidelines for epidemiological research
in Japan. The study is registered at ClinicalTrials.gov (NCT00995163). The reporting of this
study conforms to the STROBE statement (Checklist in S1 Appendix).
This study was conducted as an ad hoc analysis of the MBD-5D study. In the original study,
the sample size for the whole cohort was determined as follows: for death due to cardiovascular
disease, (1) the expected rate was 2.5 deaths per 100 person-years during the 3-year follow up
period, (2) the effect size of a drug was 20% to 25% of the relative risk, (3) the proportion of
patients to whom the drug was prescribed was one-third. With those values, 6000–7500
patients would be required for 80% power with a two-sided alpha of 0.05 [14]. On the other
hand, to examine whether a drug was associated with reduced cardiovascular hospitalization
or death due to any cause in the subcohort, the sampling fraction used was 0.4 based on the fol-
lowing assumptions: (1) the expected rate of cardiovascular hospitalization or death due to any
cause was assumed to be 13.0 events per 100 person-years during the 3-year follow-up period,
(2) the effect size of a drug was assumed to be 20% to 25% of the relative risk, and (3) the pro-
portion of patients to whom the drug was prescribed was one-third. With those values, 3000
patients would be required for 80% power with a two-sided alpha of 0.05.
Outcomes
The primary outcome of interest was total number of all-cause hospitalizations. We addi-
tionally examined cause-specific hospitalizations for cardiovascular-, infection-, and VA-
related complications, which comprise the major reasons for hospitalization in hemodialysis
patients with SHPT [13]. All-cause hospitalizations were categorized into cardiovascular
complications, infections, bleeding, malignant tumor, cachexia/uremia, chronic hepatitis/
hepatic cirrhosis, bowel obstruction, VA complications, fractures, and other or unknown
reasons. Cardiovascular-related hospitalizations were classified according to the definition
guidance (S2 Appendix) and non–cardiovascular-related hospitalizations were classified
based on physician’s judgment.
Exposure
Cinacalcet use was set as the exposure of interest. To confirm the maintenance treatment effect
of cinacalcet under the intention-to-treat effect observed in randomized controlled trials [15],
time-varying variable describing whether each patient had initiated cinacalcet by the current
time point was defined, i.e., patients contributed unexposed observations until they were initi-
ated on cinacalcet and, once initiated, these patients contributed exposed observations regard-
less of their current cinacalcet use status. As the study enrollment period was prior to the
market approval for cinacalcet in Japan, all patients were cinacalcet-naïve at baseline, allowing
for a clear definition of cinacalcet initiation (new user design) [16, 17].
Cinacalcet and hospitalization outcomes
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Covariates
Clinically relevant variables that could influence subsequent cinacalcet initiation and hospitali-
zation were considered as confounders. Time-constant confounders included demographics
such as age, gender, cause of CKD, smoking status, duration of hemodialysis, history of hyper-
parathyroidism treatment, baseline comorbidities such as diabetes mellitus and cardiovascular
disease, baseline creatinine, and baseline total protein. Time-varying medications included
VDRA, phosphate binders, and iron supplements. Time-varying laboratory tests included
Kt/V, iPTH, Ca, P, albumin, ferritin, iron, and hemoglobin. We obtained the time-varying
covariate values 3 months prior to the time-varying exposure, which in turn was ascertained 3
months prior to the time-varying outcome to ensure the correct temporal relationship (con-
founders! exposure! outcome).
Statistical analyses
Baseline continuous variables were expressed as means and standard deviations (SDs) or as
medians with 25th and 75th percentiles, as appropriate. Baseline categorical variables were
summarized as counts and proportions. These summaries were stratified by baseline iPTH lev-
els (< 200 pg/mL,� 200 to< 300 pg/mL,� 300 to< 500 pg/mL, and� 500 pg/mL; 4 strata)
as well as combined iPTH-cinacalcet use strata (any cinacalcet use during the entire follow-up
vs no cinacalcet use; 4 × 2 = 8 strata). The cut-offs at 300 and 500 pg/mL were set according
to a previous report [13]. The cut-off value at 200 pg/mL (median iPTH for patients with
iPTH< 300 pg/mL) was set in order to evaluate trends in more detail. The unadjusted changes
in serum Ca, P, and iPTH were plotted at cohort enrollment and at 1, 2, and 3 years. In addi-
tion, the proportions of patients with values recommended by the 2008 Japanese guidelines for
SHPT management (8.4–10.0 mg/dL for serum Ca, 3.5–6.0 mg/dL for serum P, and 60–180
pg/mL for serum iPTH) were also assessed [18]. The distribution of hospitalization outcomes
among patients was described as counts by using a bar plot and was supplemented with the
expected counts from a Poisson distribution with the same mean.
When the exposure is time-varying, as in our case, the confounders are also time-varying,
thereby requiring special adjustments. In particular, in the setting where the time-varying con-
founders are affected by previous exposure (i.e., confounders are also mediators of exposure
effects), the confounding effect is considered intractable by conventional methods and needs
adjustment by g-methods [19], such as the marginal structural model (MSM) using inverse
probability of treatment weights (IPTW) [20,21]. Our analysis used the stabilized weight con-
struction method described in Fewell et al. [22]. Conceptually, the IPTW method constructed
a weighted cohort (“pseudopopulation”) in which treatment assignment was random within
the baseline covariates, making time-varying confounder adjustments in the outcome model
unnecessary. Censoring was also accounted for using the inverse probability of censoring
weights (IPCW). The final weight for each observation was the product of the stabilized IPTW
and stabilized IPCW.
Since some patients experienced multiple hospitalizations, a recurrent-event model was
used. Among the various recurrent-event models available [23,24], the simplest, Andersen-Gill
model [25], was selected because more complex models incorporate time-varying confounders
into the outcome modeling, which are incompatible with MSM. The Andersen-Gill outcome
model was fitted using the IPTW-weighted data for each of the all-cause hospitalizations,
including cardiovascular-, infection-, and VA-related hospitalizations. The analysis was ini-
tially conducted without adjusting for the interaction of exposure with baseline iPTH levels.
Subsequently, the interaction was assessed to determine the potential modifying effect of
cinacalcet use on hospitalization by baseline iPTH levels at cohort enrollment. Owing to the
Cinacalcet and hospitalization outcomes
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3-month fixed interval design of the analysis, hospitalization events occasionally coincided
with the visit indicated as the censoring visit and had to be dropped, as is usually done in
MSMs. However, we also conducted a sensitivity analysis in which “missed hospitalizations”
were retained in the dataset along with the weights that were carried forward from the observa-
tions obtained immediately before.
All analyses were performed using R version 3.4 (https://www.r-project.org/]. Missing val-
ues were imputed with multiple imputation with a chained equation [26], taking individuals as
a cluster to account for the sequential nature of data points for each individual.
Results
Study population and baseline characteristics
A total of 3,276 hemodialysis patients with SHPT were included at cohort enrollment (Fig 1).
Among these, 881 had iPTH < 200 pg/mL; 1,067 had iPTH� 200 to< 300 pg/mL; 824 had
iPTH� 300 to< 500 pg/mL; and 504 had iPTH� 500 pg/mL (Table 1). The mean age was
61.9 years, and 61.5% of the patients were male. Chronic glomerulonephritis (44.9%) and dia-
betic nephropathy (24.2%) were the major primary diseases. The median duration on hemodi-
alysis was 8.3 years. S1 Table summarizes the baseline characteristics of patients who did not
use cinacalcet during the entire follow-up (never users; n = 1,892) and those who use cinacalcet
(ever users; n = 1,384) at some point. The ever users were younger, were on hemodialysis for
a longer time, were less often diabetic, had higher serum iPTH and Ca, and were more fre-
quently using VDRA and phosphate binders compared with the never users.
Descriptive statistics
The serum Ca, P, and iPTH levels stratified by baseline serum iPTH levels were plotted over
time (S1 Fig). Serum Ca levels were within the recommended range (8.4–10.0 mg/dL) for
60%–70% of patients regardless of baseline iPTH levels, but not for serum P in the highest
iPTH stratum (only 48% were within the recommended range [3.5–6.0 mg/dL]). By definition,
the guideline values for serum iPTH were not met except in the lowest stratum. However,
30%–45% of patients regardless of baseline iPTH stratum were within the recommended
range (60–180 pg/mL) at year 3.
Outcome analysis
The IPTW numerator and denominator models both had average C-statistics of around 0.65
for predicting cinacalcet initiation. The censoring numerator model had average C-statistics of
Fig 1. Eligibility flowchart.
https://doi.org/10.1371/journal.pone.0216399.g001
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0.73 for predicting censoring, whereas the censoring denominator model had average C-statis-
tics of 0.80. No complete separation issues were encountered during the modeling. The average
weights over time were consistently near the desired value of 1.0 regardless of the multiple
imputation iteration (S2 Fig).
Of 3,276 patients in the subcohort, 656 patients were censored because of renal transplanta-
tion (n = 5), initiation of peritoneal dialysis (n = 2), death (n = 506), and loss to follow-up
(n = 143). During the observation period, an average of 1.67 hospitalizations were observed
(Fig 2). The major reasons for hospitalization were as follows: 22.2% cardiovascular, 14.7% VA
complications, and 10.3% infectious diseases. The major causes of cardiovascular-related hos-
pitalization were peripheral vascular disease (20.1%), angina (19.7%), cerebrovascular disease
(18.3%), and congestive heart failure (14.0%).
Table 1. Baseline characteristics of patients at study enrollment stratified by iPTH levels.
iPTH < 200 pg/
mL
200� iPTH < 300 pg/
mL





Number of patients 881 1,067 824 504 - 3,276
Age (mean [SD]) 62.7 (12.9) 62.7 (12.6) 61.5 (12.8) 59.7 (11.9) <0.001 61.9 (12.7)
Male (%) 62.5 62.7 59.2 60.9 0.403 61.5
Primary Disease (%) <0.001
Chronic Glomerulonephritis 42.1 40.8 45.1 57.9 44.9
Diabetic Nephropathy 28.9 27.9 21.1 12.9 24.2
Dialysis vintage, years (median
[IQR])
6.7 (2.9, 12.4) 7.1 (3.1, 13.0) 8.9 (4.2, 15.2) 11.6 (7.4, 17.9) <0.001 8.3 (3.7, 14.3)
BMI, kg/m2 (mean [SD]) 21.3 (3.5) 21.4 (3.6) 21.5 (3.9) 21.2 (3.4) 0.647 21.4 (3.6)
Coronary Artery Disease (%) 26.4 26.6 24.0 23.8 0.435 25.4
Congestive Heart Failure (%) 9.3 8.2 7.3 5.8 0.123 7.9
Peripheral Vascular Disease (%) 20.3 19.1 18.4 17.7 0.625 19.1
Diabetes Mellitus (%) 36.7 35.8 29.0 18.0 <0.001 31.6
History of Parathyroidectomy (%) 4.4 5.4 6.7 10.3 <0.001 6.2
Laboratory data




Calcium, mg/dL (mean [SD]) 9.6 (0.9) 9.3 (0.9) 9.4 (0.9) 9.7 (0.9) <0.001 9.5 (0.9)
Phosphate, mg/dL (mean [SD]) 5.2 (1.3) 5.3 (1.3) 5.7 (1.4) 6.1 (1.5) <0.001 5.5 (1.4)
Albumin, g/dL (mean [SD]) 3.8 (0.4) 3.7 (0.4) 3.8 (0.4) 3.8 (0.4) 0.004 3.8 (0.4)
Kt/V (mean [SD]) 1.4 (0.3) 1.4 (0.3) 1.4 (0.3) 1.4 (0.3) 0.090 1.4 (0.3)
Dialysate Calcium, mEq/L (mean
[SD])
2.8 (0.2) 2.8 (0.2) 2.8 (0.3) 2.8 (0.3) 0.471 2.8 (0.2)
Vitamin D Receptor Agonist (%) <0.001
Both 0.0 0.2 0.0 0.2 0.1
Intravenous Only 58.2 35.3 45.4 65.7 48.7
Oral Only 29.6 37.1 27.1 11.9 28.7
Phosphate Binder (%) <0.001
Both 25.3 21.6 22.9 24.1 23.3
Non–Calcium-based Only 12.0 15.0 20.3 33.6 18.4
Calcium-based Only 49.8 46.6 41.6 29.6 43.6
BMI, body mass index; iPTH, intact parathyroid hormone; IQR, interquartile range; SD, standard deviation
aDifferences were evaluated by one-way analysis of variance or Kruskal-Wallis test for continuous variables and by chi-square test for categorical variables.
https://doi.org/10.1371/journal.pone.0216399.t001
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Modeling of the exposure-outcome relationship without adjusting for the interaction between
exposure and baseline iPTH levels yielded the following results: all-cause hospitalizations (hazard
ratio [HR]: 0.97; 95% CI: 0.80, 1.18); cardiovascular-related hospitalizations (HR: 0.85; 95% CI:
0.64, 1.14); infection-related hospitalizations (HR: 1.01; 95% CI: 0.63, 1.63); and VA-related hos-
pitalizations (HR: 1.01; 95% CI: 0.70, 1.46) (Table 2).
We then examined the interaction with baseline iPTH levels by two methods: four-level
iPTH stratification (< 200,� 200 to< 300,� 300 to< 500, and� 500 pg/mL) and two-level
iPTH stratification (< 300 and� 300 pg/mL). The stratum-specific associations are summa-
rized in Fig 3 and S2 Table. A protective association was seen due to cinacalcet use for infec-
tion-related hospitalizations in the lowest iPTH group (HR: 0.36; 95% CI: 0.14, 0.95). For the
cardiovascular-related hospitalizations, all point estimates were below 1.0, which suggests a
consistently protective association due to cinacalcet use.
Fig 2. Distribution of hospitalization outcomes for each patients. The line plot indicates the counts expected from a
Poisson distribution with the observed mean (1.67 hospitalizations over the study period), demonstrating the presence
of overdispersion.
https://doi.org/10.1371/journal.pone.0216399.g002
Table 2. Results of the outcome analysis.
Type of Hospitalization HR 95% CI P-value
All-cause 0.97 0.80, 1.18 0.746
Cardiovascular-Related 0.85 0.64, 1.14 0.282
Infection-Related 1.01 0.63, 1.63 0.957
Vascular Access-Related 1.01 0.70, 1.46 0.950
CI, confidence interval; HR, hazard ratio
HRs were adjusted for age, gender, cause of CKD, smoking status, duration of hemodialysis, history of
hyperparathyroidism treatment, baseline comorbidities (diabetes and cardiovascular disease), baseline creatinine,
baseline total protein, time-varying medications (VDRA, phosphate binders, iron supplements) and time-varying
laboratory tests (Kt/V, iPTH, Ca, P, albumin, ferritin, iron, and hemoglobin).
https://doi.org/10.1371/journal.pone.0216399.t002
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For the two-level strata analysis, the stratum-specific associations are summarized in Fig 4
and S3 Table. The stratum-specific association of cinacalcet initiation with all-cause hospitali-
zations (HR: 0.82; 95% CI: 0.67, 1.01) and VA-related hospitalizations (HR: 0.64; 95% CI: 0.40,
1.01) among patients with iPTH< 300 pg/mL demonstrated a trend toward a protective
association. Sensitivity analyses with the alternative censoring definitions did not change the
results substantially for the overall (S4 Table) and subgroup (S5 and S6 Tables) analyses.
Fig 3. Stratum-specific effects of cinacalcet initiation on hospitalization (four-level stratification). HRs were adjusted for age,
gender, cause of CKD, smoking status, duration of hemodialysis, history of hyperparathyroidism treatment, baseline comorbidities
(diabetes and cardiovascular disease), baseline creatinine, baseline total protein, time-varying medications (VDRA, phosphate binders,
iron supplements) and time-varying laboratory tests (Kt/V, iPTH, Ca, P, albumin, ferritin, iron, and hemoglobin). The P-values for the
interaction (Wald test with three degrees of freedom) were 0.221 for all-cause hospitalizations, 0.867 for cardiovascular-related
hospitalizations, 0.185 for infection-related hospitalizations, and 0.183 for VA-related hospitalizations. Abbreviations: iPTH, intact
parathyroid hormone.
https://doi.org/10.1371/journal.pone.0216399.g003
Cinacalcet and hospitalization outcomes
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Discussion
This analysis of the MBD-5D prospective cohort of hemodialysis patients aimed to elucidate
the effect of cinacalcet use on all-cause and cause-specific hospitalization outcomes. During
follow-up, 1,384 individuals initiated cinacalcet among the total cohort of 3,276 patients. The
overall hospitalization analysis yielded an HR of 0.97 (95% CI: 0.80, 1.18). A trend toward a
somewhat protective association was observed for cardiovascular-related hospitalizations (HR:
0.85; 95% CI: 0.64, 1.14), even though it is not statistically significant. In the subgroup analysis,
a protective association for infection-related hospitalizations (HR: 0.36; 95% CI: 0.14, 0.95)
was observed among patients with iPTH< 200 pg/mL. Although not confirmatory, these
Fig 4. Stratum-specific effects of cinacalcet initiation on hospitalization (two-level stratification). HRs were
adjusted for age, gender, cause of CKD, smoking status, duration of hemodialysis, history of hyperparathyroidism
treatment, baseline comorbidities (diabetes and cardiovascular disease), baseline creatinine, baseline total protein,
time-varying medications (VDRA, phosphate binders, iron supplements) and time-varying laboratory tests (Kt/V,
iPTH, Ca, P, albumin, ferritin, iron, and hemoglobin). The P-values for the interaction (Wald test with one degree of
freedom) were 0.077 for all-cause hospitalizations, 0.642 for cardiovascular-related hospitalizations, 0.530 for
infection-related hospitalizations, and 0.024 for VA-related hospitalizations. Abbreviations: iPTH, intact parathyroid
hormone.
https://doi.org/10.1371/journal.pone.0216399.g004
Cinacalcet and hospitalization outcomes
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findings suggest that association of risk attenuation for cardiovascular-related hospitalizations
and among patients with lower iPTH for infection-related hospitalizations were observed by
cinacalcet prescription.
Several studies have reported the relationship between cinacalcet use and all-cause and car-
diovascular-related hospitalizations. A pooled analysis of four randomized controlled trials
with cinacalcet in dialysis patients with SHPT indicated that cinacalcet significantly reduced
cardiovascular-related hospitalizations compared with the control group (HR: 0.61; 95% CI:
0.43, 0.86), but not all-cause hospitalizations [27]. The EVOLVE study indicated that there
was no reduction in the composite cardiovascular endpoint with cinacalcet (HR: 0.93; 95% CI:
0.85, 1.02) in the intent-to-treat analysis [11]. The prespecified analysis adjusted for baseline
parameters, parathyroidectomy, kidney transplantation, and use of commercially available
cinacalcet suggests that cinacalcet significantly reduces the risk of the composite cardiovascu-
lar endpoint (HR: 0.85; 95% CI: 0.76, 0.95). Furthermore, in the recurrent events analysis of
the EVOLVE study focusing on cardiovascular events, the results by the Andersen-Gill model
indicated that the HRs for myocardial infarction, unstable angina, and heart failure were 0.98
(95% CI: 0.78, 1.23), 0.81 (95% CI: 0.56, 1.18), and 0.90 (95% CI: 0.72, 1.13), respectively. In
this study, the HR for cardiovascular-related hospitalizations was 0.85 (95% CI: 0.64, 1.14).
Although there studies included the differences in race of subject, severity of SHPT and study
design, these results suggested the potential relationship between cinacalcet use and the lower
incidence of cardiovascular-related hospitalizations. There are several mechanisms that cina-
calcet may be associated with lower risk of cardiovascular-related hospitalizations. The first
possibility is the protective effect of cinacalcet on vascular calcification [28] and cardiac hyper-
trophy [29]. The secondary possibility is that cinacalcet reduces circulating fibroblast growth
factor 23 (FGF23) [30]. Cinacalcet treatment prevents cardiac hypertrophy via reduction in
FGF23 level [31]
In this study, the impact of cinacalcet use on infection-related hospitalizations was neutral.
Although there are no published reports investigating the relationship between cinacalcet use
and infection-related hospitalizations, the results of a meta-analysis indicated that cinacalcet
use increased upper respiratory tract infections by 79% compared with the control treatment
[32]. In this study, however, no increase in infection-related hospitalizations was observed in
any of the iPTH strata, and cinacalcet use was significantly associated with a lower incidence
of infection-related hospitalizations in patients with the lowest iPTH. Because cinacalcet could
lead to an increase in VDRA use through its serum Ca-lowering effect, it might have been
associated with the lower risk of infection-related hospitalizations due to appropriate use of
VDRA. It is clinically meaningful that cinacalcet did not increase infection-related hospitaliza-
tions, as avoiding infectious diseases in dialysis patients is an important concern. Similarly,
no relationship between cinacalcet use and VA-related hospitalizations was observed in any
patient or in most of the iPTH strata. However, a significant effect modification was observed
for iPTH 300 pg/mL in both the four-level and two-level stratification. This suggests that
cinacalcet use is associated with an opposite risk of VA-related hospitalizations in both iPHT
patients.
The study has several limitations. First, there is a possibility of unmeasured confounding
due to the nature of the analysis. Although a positive association between cinacalcet use and
infection-related hospitalizations was seen in SHPT patients with iPTH < 200 pg/mL, unmea-
sured confounding could have been involved in this subset because of the unique patient back-
ground and the low rate of cinacalcet use. Moreover, in this study, no data were obtained on
serum vitamin D, and glucocorticoid prescription. Therefore, the interaction between cinacal-
cet use and VA-related hospitalizations at iPTH 300 pg/mL may have been influenced by
unmeasured confounding factors such as hemodynamics or vascular calcification status.
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Second is the possibility of masking effect due to the censoring of death in the study as compet-
itive event. In the MBD-5D study, the adjusted IRRs of cinacalcet use for all-cause mortality in
SHPT patients were 1.07 for those with iPTH < 300 pg/mL, 0.88 for iPTH� 300 to< 500 pg/
mL, and 0.49 for iPTH� 500 pg/mL [12]. Block et al. reported that cinacalcet use showed no
survival benefit in SHPT patients with iPTH < 150 pg/mL, but showed a survival benefit in
SHPT patients with iPTH� 600 pg/mL (HR: 0.66 [95%CI: 0.53–0.83]) [11]. We handled
deaths as censored in this study and used IPCW to reduce selection bias [19]. However, it is
possible that the censoring of deaths might still have biased the effectiveness of cinacalcet use
on recurrent hospitalizations, especially in patients with higher iPTH, who showed an increase
in HR for the all-cause, infection-related, and VA-related hospitalizations. Third, the MBD-5D
study was not designed to evaluate the effectiveness of cinacalcet on case-specific hospitaliza-
tions defined in this study; therefore, it might have been underpowered. However, the sample
size in this study was not less than that of past studies.
This study has several strengths. First, we used the dataset form the well-designed prospec-
tive cohort study including more than 3,000 dialysis patients with SHPT. There were no miss-
ing data for bone-mineral markers, hospitalization outcomes and covariates. Furthermore,
as the study enrollment period was prior to the market approval for cinacalcet in Japan, all
patients were cinacalcet-naïve at baseline. We could analyze based on a clear definition of cina-
calcet initiation as new user design and adjust the potential confounders appropriately. Sec-
ond, this study include the methods used for the analyses. Appropriate methods were used for
handling patients with multiple occurring events and for analyzing recurrent outcomes. The
average number of hospitalizations in this study was 1.67 hospitalization per patient, with the
distribution indicating overdispersion. It is unlikely that each hospitalization occurred inde-
pendently, suggesting that the previous hospitalization influenced the next hospitalization.
The Andersen-Gill model can adjust for an event that contributes to the likelihood of occur-
rence of the next event, and was considered as the appropriate approach for handling multiple
events in this study.
Conclusions
Cinacalcet initiation in dialysis patients with SHPT had no effect on all-cause and cause-spe-
cific hospitalizations. Although the overall association was weak, cinacalcet may have a protec-
tive association with cardiovascular-related hospitalization in all patients and infection-related
hospitalization in patient with low iPTH.
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